https://www.selleckchem.com/pr....oducts/Cyclopamine.h
In both tumor tissues and ctDNA, mutation showed no relationship with the outcome of first I treatment and the malignant biological characteristics (P0.05). The value of mutation alone might be limited in predicting therapeutic outcome of the first I treatment in PTC. No definitive relevance was found between mutation and malignant biological features in PTC. The value of BRAF mutation alone might be limited in predicting therapeutic outcome of the first 131I treatment in PTC. No definitive relevance was found between BRAF mutat
Aimer
Commentaire
Partagez
